Summit Therapeutics Inc’s recently made public that its Co-Chief Executive Officer Zanganeh Mahkam acquired Company’s shares for reported $5.89 million on Sep 10 ’25. In the deal valued at $17.68 per share,333,394 shares were bought. As a result of this transaction, Zanganeh Mahkam now holds 556,088,090 shares worth roughly $12.09 billion.
Then, Zanganeh Mahkam bought 5,000 shares, generating $90,350 in total proceeds. Upon buying the shares at $18.07, the Co-Chief Executive Officer now owns 556,093,090 shares.
Before that, DUGGAN ROBERT W bought 333,394 shares. Summit Therapeutics Inc shares valued at $5,894,406 were divested by the Co-Chief Executive Officer at a price of $17.68 per share. As a result of the transaction, DUGGAN ROBERT W now holds 556,088,090 shares, worth roughly $12.09 billion.
Barclays initiated its Summit Therapeutics Inc [SMMT] rating to an Underweight in a research note published on September 17, 2025; the price target was $13. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Piper Sandler began covering SMMT with “Neutral” recommendation on August 19, 2025. UBS started covering the stock on July 01, 2025. It rated SMMT as “a Buy”.
Price Performance Review of SMMT
On Tuesday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock fall -5.15% to $21.75. Over the last five days, the stock has lost -2.42%. Summit Therapeutics Inc shares have risen nearly 16.87% since the year began. Nevertheless, the stocks have risen 21.88% over the past one year.
How much short interest is there in Summit Therapeutics Inc?
A steep rise in short interest was recorded in Summit Therapeutics Inc stocks on 2025-09-30, growing by 6.22 million shares to a total of 35.93 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 29.72 million shares. There was a rise of 17.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 11, 2025 when Leerink Partners began covering the stock and recommended ‘”an Underperform”‘ rating along with a $12 price target.
